<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="3500">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on October 07, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04480333</url>
  </required_header>
  <id_info>
    <org_study_id>NEUROSIVIR</org_study_id>
    <nct_id>NCT04480333</nct_id>
  </id_info>
  <brief_title>Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and NA-831</brief_title>
  <acronym>NEUROSIVIR</acronym>
  <official_title>A Randomized, Placebo-controlled Study of the Safety, Tolerability and Pharmacokinetics of Inhaled Nanoparticle Formulation of Remdesivir (GS-5734) and in Combination With NA-831 in Healthy Volunteers</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>NeuroActiva, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>NeuroActiva, Inc.</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The clinical study is designed to evaluate the safety, tolerability and pharmacokinetics of
      inhaled nanoparticle nanoparticle formulation of Remdesivir (GS-5734) alone and in
      combination with NA-831 in 48 healthy volunteers.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      It has been discovered that SARS-CoV-2 viruses (Covid-19) can directly invade the nervous
      system of patients, instead of injuring the nervous system through the immune response.
      Neurotropism is one common feature of Covid-19. Such neuro-invasive propensity of Covid-19
      has been documented almost for all the Beta-coronaviruses including SARS-CoV and MERS-CoV.

      Increasing evidence suggests that infection with Sars-CoV-2 causes neurological deficits in a
      substantial proportion of affected patients. It was observed that patients surviving COVID-19
      are at high risk for subsequent development of neurological disease and in particular
      Alzheimer's disease.

      NA-831 is a new neuroprotective and neurogenesis drug that has been demonstrated its
      promising safety and efficacy in Phase 2A for the treatment of early onset of Alzheimer's
      disease. NA-831 in oral formulation is well tolerated NA-831 with no adverse effects. NA-831
      in oral formulation exhibits predictable pharmacokinetics including dose-dependent exposure
      linearity and low variability.

      Based on animal studies, NA-831 can provide effective interventions during the severe acute
      respiratory syndrome, and provide appropriate rehabilitation measures afterwards.

      Remdesivir (GS-5734) intravenous formulation has been approved by the FDA under the emergency
      use authorization for potential treatment of severe cases of Covid-19.

      It was found the upper respiratory tract is the most prevalent site of SARS-CoV-2 infection
      early in disease. Delivering drugs directly to the primary site of infection with a
      nebulizer, inhaled nanoparticle formulation may enable more targeted and accessible
      administration in non-hospitalized patients and potentially lower systemic exposure to the
      drug.

      The study is designed to evaluate the safety, tolerability and pharmacokinetics of a new
      nanoparticle formulation of Remdesivir (GS-5734) and combination therapy with NA-831 in
      healthy volunteers.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Anticipated">September 15, 2020</start_date>
  <completion_date type="Anticipated">March 31, 2021</completion_date>
  <primary_completion_date type="Anticipated">December 31, 2020</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <intervention_model_description>The dose escalation given to healthy volunteers across the following cohorts:
NA-831 cohorts:
0.1 mg/kg NA-831, number of subjects N=2 and 2 subjects on placebos 0.2 mg/kg NA-831, number of subjects N=4 and 2 subjects on placebos 0.5 mg/kg NA-831, number of subjects N=4 and 2 subjects on placebos
GS-5734 cohorts:
mg/kg GS-5734, number of subjects N=2 and 2 subjects on placebos
mg/kg GS-5734, number of subjects N=4 and 2 subjects on placebos
4 mg/kg GS-5734, number of subjects N=4 and 2 subjects on placebos
NA-831 plus GS-5734 cohorts:
0.1 mg/kg NA-831 plus 1 mg/kg GS-5734, number of subjects N=2 and 2 subjects on placebos 0.2 mg/kg NA-831 plus 2 mg/kg GS-5734, number of subjects N=4 and 2 subjects on placebos 0.5 mg/kg NA-831 plus 4 mg/kg GS-5734, number of subjects N=4 and 2 subjects on placebos.</intervention_model_description>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Proportion of Participants Experiencing any Treatment-Emergent Adverse Events</measure>
    <time_frame>First dose date up to Day 30 Follow-up Assessment</time_frame>
    <description>AEs will be assessed using Common Terminology Criteria for Adverse Events (CTCAE) V5.0</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Proportion of Participants Experiencing any Treatment-Emergent Graded Laboratory Abnormalities</measure>
    <time_frame>First dose date up to Day 30 Follow-up Assessment</time_frame>
    <description>This will be assessed at various time points by clinical laboratory tests and vital signs.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Maximum Concentration (Cmax) - Pharmacokinetic Assessment</measure>
    <time_frame>7 days</time_frame>
    <description>Monitoring of the levels of drugs in subject sera at various time points to elucidate the maximum concentration (Cmax) of NA-831 and GS-5734 in human serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to Maximum Concentration (Tmax) - Pharmacokinetic Assessment</measure>
    <time_frame>7 days</time_frame>
    <description>Monitoring of the levels of drugs in subject sera at various time points to elucidate the time to maximum concentration (Tmax) of NA-831 and GS-5734 in human serum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUC calculated from time of administration to the last measurable concentration (AUC0-last) - Pharmacokinetic Assessment</measure>
    <time_frame>7 days</time_frame>
    <description>Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve from time of administration to the last measurable of NA-831 and GS-5734</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Area Under the Curve Extrapolated to Infinity (AUC0-∞)</measure>
    <time_frame>7 days</time_frame>
    <description>Monitoring of the levels of drugs in subject sera at various time points to elucidate the area under the curve extrapolated to infinity (AUC0-∞) of NA-831 and GS-5734</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Half-Life (t1/2) - Pharmacokinetic Assessment</measure>
    <time_frame>7 days</time_frame>
    <description>Monitoring of the levels of drugs in subject sera at various time points to elucidate the half-life (t1/2) of NA-831 and GS-5734 in human serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Volume of Distribution (Vd) - Pharmacokinetic Assessment</measure>
    <time_frame>7 days</time_frame>
    <description>Monitoring of the levels of drugs in subject sera through various time points to elucidate the volume of distribution (Vd) of NA-831 and GS-5734 in human serum.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clearance [CL] - Pharmacokinetic Assessment</measure>
    <time_frame>7 days</time_frame>
    <description>Monitoring of the levels of drugs in subject sera through at various time points to elucidate clearance [CL] of NA-831 and GS-5734 in human serum.</description>
  </secondary_outcome>
  <number_of_arms>12</number_of_arms>
  <enrollment type="Anticipated">45</enrollment>
  <condition>Covid19</condition>
  <condition>Corona Virus Infection</condition>
  <condition>Severe Acute Respiratory Syndrome</condition>
  <condition>Severe Acute Respiratory Infection</condition>
  <condition>Severe Acute Respiratory Syndrome (SARS) Pneumonia</condition>
  <condition>Severe Acute Respiratory Syndrome of Upper Respiratory Tract</condition>
  <condition>Neurodegeneration</condition>
  <condition>Neuroinflammatory Response</condition>
  <arm_group>
    <arm_group_label>Drug: NA-831 - 0.10 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 Subjects will take inhaled formulation of NA-831 once a day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparable Placebo- 0.10 mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 subjects will take inhaled formulation of placebo once a day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: NA-831 - 0.20 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Subjects will take inhaled formulation of NA-831 once a day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparable Placebo- 0.20 mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 subjects will take inhaled formulation of placebo once a day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: GS-5734 - 1.00 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparable Placebo- 1.00 mg.kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drug: GS-5734 - 2.00 mg/kg</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Subjects will take inhaled formulation of GS-5734 once a day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Comparable Placebo - 2.00 mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 Subjects will take inhaled formulation of GS-5734 once a day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>3 Subjects- will take inhaled formulation NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg) once/day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- 0.10- mg/kg placebo+1.00 mg mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 Subjects - inhaled formulation of placebo once/day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Drugs: NA-831( 0.20 mg/kg) + GS-5734 (2.00 mg/kg)</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>6 Subjects- inhaled formulation of NA-831 (0.20 mg/kg) + GS-5734 (2.00 mg/kg) once/day for 5 days</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo- 0.20 mg/kg + 2.00mg/kg</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>3 Subjects- inhaled formulation of placebo once/day for 5 days</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: NA-831 - 0.10 mg/kg</intervention_name>
    <description>NA-831 in nanoparticle inhalation formulation</description>
    <arm_group_label>Drug: NA-831 - 0.10 mg/kg</arm_group_label>
    <other_name>NA-831 is a neuroprotective and neurogenesis drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo- 0.10 mg/kg</intervention_name>
    <description>Placebo in nanoparticle inhalation formulation</description>
    <arm_group_label>Comparable Placebo- 0.10 mg/kg</arm_group_label>
    <other_name>Placebo Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: NA-831 - 0.20 mg/kg</intervention_name>
    <description>NA-831 in nanoparticle inhalation formulation</description>
    <arm_group_label>Drug: NA-831 - 0.20 mg/kg</arm_group_label>
    <other_name>NA-81 is a neuroprotective drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo- 0.20 mg/kg</intervention_name>
    <description>Placebo in nanoparticle inhalation formulation</description>
    <arm_group_label>Comparable Placebo- 0.20 mg/kg</arm_group_label>
    <other_name>Placebo Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: GS-5734 - 1.00 mg/kg</intervention_name>
    <description>GS-5734 in nanoparticle inhaled formulation</description>
    <arm_group_label>Drug: GS-5734 - 1.00 mg/kg</arm_group_label>
    <other_name>GS-5734 (Remdesivir) is an antiviral drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo- 1.00 mg/kg</intervention_name>
    <description>Placebo in nanoparticle inhalation formulation</description>
    <arm_group_label>Comparable Placebo- 1.00 mg.kg</arm_group_label>
    <other_name>Placebo Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drug: GS-5734 - 2.00 mg/kg</intervention_name>
    <description>GS-5734 in nanoparticle inhaled formulation</description>
    <arm_group_label>Drug: GS-5734 - 2.00 mg/kg</arm_group_label>
    <other_name>GS-5734 (Remdesivir) is an anti-viral drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo- 2.00 mg/kg</intervention_name>
    <description>Placebo in nanoparticle inhaled formulation</description>
    <arm_group_label>Comparable Placebo - 2.00 mg/kg</arm_group_label>
    <other_name>Placebo Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)</intervention_name>
    <description>The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation</description>
    <arm_group_label>Drugs: NA-831 (0.10 mg/kg) plus GS-5734 (1.00 mg/kg)</arm_group_label>
    <other_name>Combination therapy of NA-831 a neuroprotective drug and GS-5734 an antiviral drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo 0.10 mg + 1.00 mg/kg</intervention_name>
    <description>The combined placebo are in nanoparticle inhaled formulation</description>
    <arm_group_label>Placebo- 0.10- mg/kg placebo+1.00 mg mg/kg</arm_group_label>
    <other_name>Placebo Comparator</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Drugs: NA-831 (0.20 mg/kg) plus GS-5734 (2.00 mg/kg)</intervention_name>
    <description>The combined NA-831 and GS-5734 are in nanoparticle inhaled formulation</description>
    <arm_group_label>Drugs: NA-831( 0.20 mg/kg) + GS-5734 (2.00 mg/kg)</arm_group_label>
    <other_name>Combination therapy of NA-831, a neuroprotective drug and GS-5734, an antiviral drug</other_name>
  </intervention>
  <intervention>
    <intervention_type>Combination Product</intervention_type>
    <intervention_name>Placebo 0.20 mg + 2.00 mg/kg</intervention_name>
    <description>Placebo 0.10 mg + 1.00 mg/kg</description>
    <arm_group_label>Placebo- 0.20 mg/kg + 2.00mg/kg</arm_group_label>
    <other_name>Placebo Comparator</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        INCLUSION CRITERIA:

          1. Healthy adult volunteers, aged 21 to 50 years old, men or women.

          2. Subjects negative for human immunodeficiency virus (HIV antibody screen), Hepatitis B
             virus surface Antigen (HBsAg) and Hepatitis C virus (HCV antibody screen).

          3. Subjects who are willing to comply with the requirements of the study protocol, attend
             scheduled visits and make themselves available for the duration of the study with
             access to a consistent means of telephone contact.

          4. Subjects who give written informed consent approved by the Internal Review Board
             governing the site.

          5. Satisfactory baseline medical assessment as assessed by physical examination and a
             stable health status. Normal laboratory values must be within normal range of the
             assessing site or show minor variations that are deemed not clinically significant as
             judged by the Investigator and acceptable for study entry.

          6. Accessible vein in the forearm for blood collection.

          7. Female subjects of childbearing potential may be enrolled in the study if they have
             negative urine pregnancy tests on the day of screening and day of admission.

          8. Female subjects of non-childbearing potential due to surgical sterilization
             (hysterectomy or bilateral oophorectomy or tubal ligation) or menopause.

          9. Both male (if he has a partner of childbearing potential) and female subjects (of
             childbearing potential) must agree to use adequate and reliable contraceptive measures
             (e.g. spermicides, condoms, contraceptive pills, etc.) or practice abstinence
             throughout the duration of the study (up to 30 days post-dosing).

        EXCLUSION CRITERIA:

          1. Subject previously diagnosed with COVID-19 or had been issued with a quarantine order
             by the Center of Disease Control (CDC).

          2. Presence of acute infection in the preceding 14 days, or presence of a temperature ≥
             100.0 ˚F (oral or tympanic temperature assessment), or acute symptoms of any severity
             on the scheduled date of admission.

          3. History of severe drug and / or food allergies and / or known allergies to the trial
             product or its components.

          4. Female subject who is pregnant or breast-feeding.

          5. History or presence of cardiovascular, respiratory, hepatic, renal, gastrointestinal,
             , or immunosuppressive disorders.

          6. Any neurological disease or history of significant neurological disorder (e.g.
             meningitis, seizures, multiple sclerosis, vasculitis, migraines, Guillain-Barré
             syndrome [genetic/congenital or acquired]).

          7. Evidence of clinically significant anemia (HB &lt; 10 g/dL) or any other significant
             active hematological disease, or having donated &gt; 450 mL of blood within the past
             three (3) months.

          8. Participation or planned participation in a study involving the administration of an
             investigational compound within the past four (4) months or during this study period.

          9. Receipt of immunoglobulins and/or any blood products within nine (9) months of study
             enrolment or planned administration of any of these products during the study period.

         10. Evidence of Hepatitis B or C or HIV by laboratory testing.

         11. A positive test result for drugs of abuse (except a positive test result associated
             with prescription medication that has been reviewed and approved by the investigator)
             or alcohol at screening.

         12. Administration of any licensed vaccine within 30 days before the first study vaccine
             dose.

         13. Both male (if he has a partner of childbearing potential) and female subjects (of
             childbearing potential) who are unwilling to use adequate contraception or practice
             abstinence throughout the duration of the study (up to 84 days post-dosing).

         14. Any condition that, in the opinion of the Investigator, would complicate or compromise
             the study or well-being of the subject.

             -
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>50 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Lloyd Tran, PhD</last_name>
    <role>Study Director</role>
    <affiliation>NeuroActiva, Inc.</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Brian Tran, MD</last_name>
    <phone>1-415-941-3133</phone>
    <email>BTran@neuroactiva.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Markku Kurkinen, PhD</last_name>
    <phone>1-415-941-3133</phone>
    <email>MKurkinen@neuroactiva.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Coronavirus Research Institute</name>
      <address>
        <city>Sunnyvale</city>
        <state>California</state>
        <zip>94086</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Nguyen, MD</last_name>
      <email>research@covri.org</email>
    </contact>
    <contact_backup>
      <last_name>Lloyd Tran, PhD</last_name>
      <email>LTran@neuroactiva.com</email>
    </contact_backup>
    <investigator>
      <last_name>Markku Kurkinen, PhD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 13, 2020</study_first_submitted>
  <study_first_submitted_qc>July 16, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 21, 2020</study_first_posted>
  <last_update_submitted>July 16, 2020</last_update_submitted>
  <last_update_submitted_qc>July 16, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 21, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Covid-19</keyword>
  <keyword>Corona Virus Infection</keyword>
  <keyword>Severe Acute Respiratory Syndrome</keyword>
  <keyword>Severe Acute Respiratory Infection</keyword>
  <keyword>Severe Acute Respiratory Syndrome (SARS) Pneumonia</keyword>
  <keyword>Severe Acute Respiratory Syndrome of Upper Respiratory Tract</keyword>
  <keyword>Neurodegeneration</keyword>
  <keyword>Neuroinflammation</keyword>
  <keyword>Cognitive decline</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infection</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Respiratory Tract Infections</mesh_term>
    <mesh_term>Virus Diseases</mesh_term>
    <mesh_term>Severe Acute Respiratory Syndrome</mesh_term>
    <mesh_term>Coronavirus Infections</mesh_term>
    <mesh_term>Pneumonia</mesh_term>
    <mesh_term>Syndrome</mesh_term>
    <mesh_term>Nerve Degeneration</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Antiviral Agents</mesh_term>
    <mesh_term>Neuroprotective Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>We plan to share the Study Protocol</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_time_frame>90 days after the completion of the study</ipd_time_frame>
    <ipd_access_criteria>to be determined</ipd_access_criteria>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

